Selling Buzz: NRx Pharmaceuticals Inc. [NRXP] 10% Owner Javitt Daniel C. sells 784,063 shares of the company

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. NRx Pharmaceuticals Inc. shares valued at $791,433 were sold by Javitt Daniel C. on Jul 29. At $1.01 per share, Javitt Daniel C. sold 784,063 shares. The insider’s holdings dropped to 9,872,901 shares worth approximately $7.9 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Javitt Daniel C. sold 86,459 shares, netting a total of over 55,861 in proceeds. Following the sale of shares at $0.65 each, the insider now holds 12,656,964 shares.

Before that, Javitt Daniel C. had sold 115,657 shares from its account. In a trade valued at $76,947, the 10% Owner traded NRx Pharmaceuticals Inc. shares for $0.67 each. Upon closing the transaction, the insider’s holdings decreased to 115,657 shares, worth approximately $10.19 million.

Analyzing NRXP’s Price Performance

On Thursday, NRx Pharmaceuticals Inc. [NASDAQ: NRXP] plunged -1.85% to $0.80. The stock’s lowest price that day was $0.76, but it reached a high of $0.832 in the same session. During the last five days, there has been a surge of approximately 52.89%. Over the course of the year, NRx Pharmaceuticals Inc. shares have dropped approximately -83.27%. Shares of the company reached a 52-week high of $5.1500 on 01/06/22 and a 52-week low of $0.4899 on 05/26/22. A 50-day SMA is recorded $0.6287, while a 200-day SMA reached $3.2496. Nevertheless, trading volume fell to 1.73 million shares from 3.16 million shares the previous day.

Support And Resistance Levels for NRx Pharmaceuticals Inc. (NRXP)

According to the 24-hour chart, there is a support level at 0.7626, which, if violated, would cause prices to drop to 0.7253. In the upper region, resistance lies at 0.8346. The next price resistance is at 0.8693. RSI (Relative Strength Index) is 62.99 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.1582, which suggests the price will decrease in the coming days. Percent R is at 45.47%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is NRx Pharmaceuticals Inc. subject to short interest?

Stocks of NRx Pharmaceuticals Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by 20000.0 shares to 1.53 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 1.55 million shares. A decline of -1.31% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.45 of the overall float, the days-to-cover ratio (short ratio) decline to 3.45.

Which companies own the most shares of NRx Pharmaceuticals Inc. (NRXP)?

According to Armistice Capital LLC filings, the company currently owns 6,259,781 shares, which is about 9.39% of the total NRXP shares outstanding. With the completion of the sale transaction, The Vanguard Group, Inc.’s stake is now worth $639,994. In its current portfolio, Renaissance Technologies LLC holds 139,003 shares valued at $83402.0.

In terms of NRx Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $2.00 in the next 12 months, up nearly 146.91% from the previous closing price of $0.81. Analysts anticipate NRx Pharmaceuticals Inc. stock to reach $2.00 by 2022, with the lowest price target being $2.00. In spite of this, 1 analysts ranked NRx Pharmaceuticals Inc. stock as a Buy at the end of 2022.


Please enter your comment!
Please enter your name here